Guangzhou Health Institute research confirms that there is a new cure for multi-drug-resistant tuberculosis

Zhang Tianyu, State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences & Guangdong-Hong Kong-Macao Respiratory System Infectious Diseases Joint Experimental Researcher Zhang Tianyu's research team and Zhong Nanshan, Academician of the Chinese Academy of Engineering, University of Auckland & University of Otago Professor Cook Gregory and Russia Professor Maslov Dmitry of the Academy of Sciences has confirmed that the new drug TB47 and the patent expired old drug form a pure oral combination, which is expected to cure multidrug-resistant tuberculosis within 4 months

Tuberculosis, commonly known as tuberculosis, is a fatal disease caused by Mycobacterium tuberculosis (TB bacterium for short), and pulmonary tuberculosis is the most common

The new anti-tuberculosis drug TB47 that targets the cytochrome bc1 oxidase complex of the respiratory chain of mycobacterium previously developed by Zhang Tianyu’s research group and clofazimine have a unique combination of bactericidal and sterilization activities.

However, this therapy uses injection drugs, and pure oral treatment is the current trend in the development of anti-tuberculosis drugs and new therapies.

The study shows that the combination of TB47 and the patent expired oral medicine has a good cure effect for MDR tuberculosis.

The treatment time of pyrazinamide-free TB47+clofazimine+linezolid triple-drug combination to achieve a complete cure takes 5-6 months, which is basically close to the course of treatment of common tuberculosis with four first-line drugs